A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.

Cancer6.20
Volume: 127, Issue: 21, Pages: 3975 - 3984
Published: Nov 1, 2021
Abstract
Background null Several clinical studies of vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) therapy as a second-line treatment for biliary tract cancer (BTC) have shown modest efficacy. In this study, surufatinib was evaluated as a second-line VEGFR therapy in patients with BTC. null Methods null This was a single-arm, multicenter, open-label phase 2 study conducted in China. The study enrolled...
Paper Details
Title
A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
Published Date
Nov 1, 2021
Journal
Volume
127
Issue
21
Pages
3975 - 3984
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.